Australian cell therapy company launches mid-stage clinical trial

Latest NewsAusBiotech

Australian cell therapy company Chimeric Therapeutics has launched its Phase 1/2 multi-centre clinical trial for its CHM CDH17 CAR T therapy.

The company said the trial is now open for enrolment at SCRI Oncology Partners in Nashville.

“We are thrilled to open the first-in-human study of CDH17 CAR T cell therapy for patients with advanced GI cancers. Almost 5,000,000 patients are diagnosed with GI cancers worldwide each year, and treatment of these patients in the advanced clinical setting represents an important unmet medical need,” said Dr Meredith Pelster, Associate Director at SCRI and principal investigator for the clinical trial.

“Initiation of the CHM CDH17 CAR T clinical trial marks a major value-creating milestone for Chimeric, as we advance this high market potential asset from preclinical to clinical stage,” said Dr Rebecca McQualter, chief operating officer of Chimeric Therapeutics.

The trial is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 (CHM 2101) and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.

Chimeric said additional clinical trial sites are anticipated to open in the second half of 2024.